DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Meyer T, Palmer DH, Cheng A-L, Hocke J, Loembé A-B, Yen C-J.
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Liver Int 2017;
37 (07) 1047-1055
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.